{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:23:15Z","timestamp":1791876195372,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T00:00:00Z","timestamp":1525737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00296-018-4041-1","type":"journal-article","created":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T01:22:06Z","timestamp":1525742526000},"page":"1363-1383","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Efficacy and safety of interleukin-1 antagonists in rheumatoid arthritis: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5206-6197","authenticated-orcid":false,"given":"Shekoufeh","family":"Nikfar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8015-1834","authenticated-orcid":false,"given":"Parisa","family":"Saiyarsarai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9963-6302","authenticated-orcid":false,"given":"Bereket Molla","family":"Tigabu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0123-1209","authenticated-orcid":false,"given":"Mohammad","family":"Abdollahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,8]]},"reference":[{"issue":"1","key":"4041_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL et al (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68(1):1\u201326","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"4041_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GRet al (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75(1):3\u201315","journal-title":"Ann Rheum Dis"},{"key":"4041_CR3","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1136\/annrheumdis-2013-204627","volume":"73","author":"M Cross","year":"2014","unstructured":"Cross M, Smith E, Hoy D et al (2014) The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 73:1316\u20131322","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"4041_CR4","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2165\/00019053-200321130-00002","volume":"21","author":"B Blumenauer","year":"2003","unstructured":"Blumenauer B, Cranney A, Clinch J, Tugwell P (2003). Quality of life in patients with rheumatoid arthritis: which drugs might make a difference. Pharmacoeconomics 21(13):927\u2013940","journal-title":"Pharmacoeconomics"},{"issue":"23","key":"4041_CR5","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365(23):2205\u20132219","journal-title":"N Engl J Med"},{"issue":"6937","key":"4041_CR6","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nature01661","volume":"423","author":"GS Firestein","year":"2003","unstructured":"Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423(6937):356\u2013361","journal-title":"Nature"},{"issue":"6","key":"4041_CR7","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1136\/ard.2009.126532","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Landewe R, Breedveld FC et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6):964\u2013975","journal-title":"Ann Rheum Dis"},{"key":"4041_CR8","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1177\/0091270005277938","volume":"45","author":"T Doan","year":"2005","unstructured":"Doan T, Massarotti E (2005) Rheumatoid arthritis: an overview of new and emerging therapies. J Clin Pharmacol 45:751\u2013762","journal-title":"J Clin Pharmacol"},{"key":"4041_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.vhri.2015.10.003","volume":"9","author":"A Hashemi-Meshkini","year":"2016","unstructured":"Hashemi-Meshkini A, Nikfar S, Glaser E, Jamshidi A, Hosseini SA (2016) Cost-effectiveness analysis of tocilizumab in comparison with infliximab in iranian rheumatoid arthritis patients with inadequate response to tDMARDs: a multistage Markov model. Value Health Reg Issues 9:42\u201348","journal-title":"Value Health Reg Issues"},{"issue":"9","key":"4041_CR10","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s00296-016-3484-5","volume":"36","author":"S Ahmadiani","year":"2016","unstructured":"Ahmadiani S, Nikfar S, Karimi S, Jamshidi AR, Akbari-Sari A, Kebriaeezadeh A (2016) Rituximab as first choice for patients with refractory rheumatoid arthritis: cost-effectiveness analysis in Iran based on a systematic review and meta-analysis. Rheumatol Int 36(9):1291\u20131300","journal-title":"Rheumatol Int"},{"issue":"3","key":"4041_CR11","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1097\/01.rhu.0000166673.34461.33","volume":"11","author":"GS Firestein","year":"2005","unstructured":"Firestein GS (2005) Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J Clin Rheumatol 11(3):S39\u2013S44","journal-title":"J Clin Rheumatol"},{"key":"4041_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jneuroim.2015.02.002","volume":"280","author":"E Kosek","year":"2015","unstructured":"Kosek E, Altawil R, Kadetoff D et al (2015) Evidence of different mediators of central inflammation in dysfunctional and inflammatory pain\u2014interleukin-8 in fibromyalgia and interleukin-1 \u03b2 in rheumatoid arthritis. J Neuroimmunol 280:49\u201355","journal-title":"J Neuroimmunol"},{"issue":"5","key":"4041_CR13","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s10067-010-1654-5","volume":"30","author":"J Bao","year":"2011","unstructured":"Bao J, Yue T, Liu W et al (2011) Secondary failure to treatment with recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis. Clin Rheumatol 30(5):697\u2013701","journal-title":"Clin Rheumatol"},{"issue":"9","key":"4041_CR14","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1136\/ard.2003.016014","volume":"63","author":"SB Cohen","year":"2004","unstructured":"Cohen SB, Moreland LW, Cush JJ et al (2004) A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 63(9):1062\u20131068","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4041_CR15","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/art.20221","volume":"50","author":"MC Genovese","year":"2004","unstructured":"Genovese MC, Cohen S, Moreland L et al (2004) Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheumatol 50(5):1412\u20131419","journal-title":"Arthritis Rheumatol"},{"key":"4041_CR16","first-page":"503","volume":"5","author":"ER Lungoci","year":"2015","unstructured":"Lungoci ER, Hacard F, Nicolas JF, Berard F (2015). Anakinra delayed skin allergy expressing as both injection site reactions and generalized exanthema. Eur J Dermatol 5:503\u2013504","journal-title":"Eur J Dermatol"},{"issue":"4","key":"4041_CR17","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/art.10870","volume":"48","author":"RM Fleischmann","year":"2003","unstructured":"Fleischmann RM, Schechtman J, Bennett R et al (2003) Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheumatol 48(4):927\u2013934","journal-title":"Arthritis Rheumatol"},{"issue":"18","key":"4041_CR18","first-page":"iii","volume":"8","author":"W Clark","year":"2004","unstructured":"Clark W, Jobanputra P, Barton P, Burls A (2004) The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis. Health Technol Assess (Winch Engl) 8(18):iii\u2013iv (ix\u2013x, 1\u2013105)","journal-title":"Health Technol Assess (Winch Engl)"},{"issue":"12","key":"4041_CR19","first-page":"2398","volume":"33","author":"G Gartlehner","year":"2006","unstructured":"Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN (2006) The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 33(12):2398\u20132408","journal-title":"J Rheumatol"},{"key":"4041_CR20","first-page":"Cd008794","volume":"2","author":"JA Singh","year":"2011","unstructured":"Singh JA, Wells GA, Christensen R et al (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane database of systematic reviews 2:Cd008794","journal-title":"Cochrane database of systematic reviews"},{"key":"4041_CR21","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1477-7525-12-102","volume":"12","author":"JP Jansen","year":"2014","unstructured":"Jansen JP, Buckley F, Dejonckheere F, Ogale S (2014). Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs: a systematic review and network meta-analysis. Health Qual Life Outcomes 12:102","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"4041_CR22","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.rbr.2016.07.008","volume":"56","author":"VP Cabral","year":"2016","unstructured":"Cabral VP, Andrade CA, Passos SR, Martins MF, Hokerberg YH (2016) Severe infection in patients with rheumatoid arthritis taking anakinra, rituximab, or abatacept: a systematic review of observational studies. Rev Bras Reumatol 56(6):543\u2013550","journal-title":"Rev Bras Reumatol"},{"key":"4041_CR23","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1093\/rheumatology\/kem072","volume":"46","author":"R Nixon","year":"2007","unstructured":"Nixon R, Bansback N, Brennan A (2007) The efficacy of inhibiting tumour necrosis factor \u03b1 and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology 46:1140\u20131147","journal-title":"Rheumatology"},{"issue":"6","key":"4041_CR24","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3899\/jrheum.090074","volume":"36","author":"M Mertens","year":"2009","unstructured":"Mertens M, Singh JA (2009) Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 36(6):1118\u20131125","journal-title":"J Rheumatol"},{"key":"4041_CR25","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","volume":"31","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Blackmore H et al (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and edithors. Rheumatol Int 31:1409\u20131417","journal-title":"Rheumatol Int"},{"issue":"4","key":"4041_CR26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ et al (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64(4):401\u2013406","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"4041_CR27","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1002\/art.10578","volume":"46","author":"G Nuki","year":"2002","unstructured":"Nuki G, Bresnihan B, Bear MB, McCabe D (2002) Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 46(11):2838\u20132846","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"4041_CR28","first-page":"1538","volume":"35","author":"X Le Lo\u00ebt","year":"2008","unstructured":"Le Lo\u00ebt X, Nordstr\u00f6m D, Rodriguez M et al (2008) Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA trial. J Rheumatol 35(8):1538\u20131544","journal-title":"J Rheumatol"},{"issue":"6","key":"4041_CR29","first-page":"1103","volume":"31","author":"B Bresnihan","year":"2004","unstructured":"Bresnihan B, Newmark R, Robbins S, Genant HK (2004) Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. J Rheumatol 31(6):1103\u20131111","journal-title":"J Rheumatol"},{"issue":"8","key":"4041_CR30","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/ard.2005.048371","volume":"65","author":"RM Fleischmann","year":"2006","unstructured":"Fleischmann RM, Tesser J, Schiff MH et al (2006) Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 65(8):1006\u20131012","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"4041_CR31","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2","volume":"41","author":"B Bresnihan","year":"1998","unstructured":"Bresnihan B, Alvaro-Gracia JM, Cobby M et al (1998) Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheumatol 41(12):2196\u20132204","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"4041_CR32","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/art.10141","volume":"46","author":"S Cohen","year":"2002","unstructured":"Cohen S, Hurd E, Cush J et al (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 46(3):614\u2013624","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"4041_CR33","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1136\/annrheumdis-2013-204588","volume":"73","author":"C Gaujoux-Viala","year":"2014","unstructured":"Gaujoux-Viala C, Nam J, Ramiro S et al (2014) Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 73(3):510\u2013515","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4041_CR34","doi-asserted-by":"publisher","first-page":"e30275","DOI":"10.1371\/journal.pone.0030275","volume":"7","author":"KJ Aaltonen","year":"2012","unstructured":"Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordstr\u00f6m DC, Blom M (2012) Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 7(1):e30275","journal-title":"PLoS One"},{"issue":"35","key":"4041_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20350","volume":"20","author":"M Stevenson","year":"2016","unstructured":"Stevenson M, Archer R, Tosh J et al (2016) Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technol Assess 20(35):1\u2013610","journal-title":"Health Technol Assess"},{"issue":"7","key":"4041_CR36","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/rheumatology\/ker146","volume":"50","author":"JB Galloway","year":"2011","unstructured":"Galloway JB, Hyrich KL, Mercer LK et al (2011). The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 50(7):1341\u20131342","journal-title":"Rheumatology"},{"issue":"1","key":"4041_CR37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2007.083188","volume":"68","author":"C Salliot","year":"2009","unstructured":"Salliot C, Dougados M, Gossec L (2009) Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 68(1):25\u201332","journal-title":"Ann Rheum Dis"},{"key":"4041_CR38","unstructured":"Food and Drug Administration (2012) Kineret (anakinra), highlights of prescribing information. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103950s5136lbl\n                    \n                  . Accessed Dec 2012"},{"issue":"1","key":"4041_CR39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/1471-2474-12-153","volume":"12","author":"R Alten","year":"2011","unstructured":"Alten R, Gomez-Reino J, Durez P (2011) Efficacy and safety of the human anti-ILbeta monoclonal antibody canakinumab in rheumatoid arthritis: result of 12-week, phase II, dose-finding study. BMC Musculoskelet Disord 12(1):153","journal-title":"BMC Musculoskelet Disord"},{"key":"4041_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-12-153","author":"R1 Alten","year":"2011","unstructured":"Alten R1, Gomez-Reino J, Durez P et al (2011) Efficacy and safety of the human anti-IL-1\u03b2 monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study. BMC Musculoskelet Disord. \n                    https:\/\/doi.org\/10.1186\/1471-2474-12-153","journal-title":"BMC Musculoskelet Disord"},{"issue":"10","key":"4041_CR41","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.clinthera.2012.09.009","volume":"34","author":"MH Hoffman","year":"2012","unstructured":"Hoffman MH, Throne LM, Amar JN et al (2012) Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extention study. Clin Ther 34(10):2091\u20132103","journal-title":"Clin Ther"},{"issue":"12","key":"4041_CR42","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1136\/annrheumdis-2012-201409","volume":"71","author":"O Petryana","year":"2012","unstructured":"Petryana O, Cush JJ, Efthimiou P (2012) IL-1 Trap rilonacept in refractory adult onset Still\u2019s disease. Ann Rheum Dis 71(12):2056\u20132057","journal-title":"Ann Rheum Dis"},{"key":"4041_CR43","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman GD, Tetzlaff et al (2009) The PRISMA statement for reporting systematic review and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700","journal-title":"BMJ"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-018-4041-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-018-4041-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-018-4041-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T19:39:50Z","timestamp":1557257990000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-018-4041-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,8]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["4041"],"URL":"https:\/\/doi.org\/10.1007\/s00296-018-4041-1","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,8]]},"assertion":[{"value":"20 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}